Aethlon Medical (NASDAQ:AEMD) Releases Earnings Results, Misses Estimates By $2.04 EPS

Aethlon Medical (NASDAQ:AEMD) released its earnings results on Wednesday. The medical equipment provider reported ($3.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.70) by ($2.04), FiscalAI reports.

Aethlon Medical Stock Down 3.2%

NASDAQ:AEMD opened at $4.20 on Thursday. The firm’s fifty day simple moving average is $6.43 and its 200 day simple moving average is $15.02. The stock has a market cap of $1.09 million, a P/E ratio of -0.12 and a beta of 1.83. Aethlon Medical has a twelve month low of $4.02 and a twelve month high of $84.40.

Analysts Set New Price Targets

AEMD has been the subject of a number of recent research reports. Wall Street Zen upgraded shares of Aethlon Medical to a “sell” rating in a report on Saturday, August 30th. Weiss Ratings restated a “sell (e+)” rating on shares of Aethlon Medical in a research report on Wednesday, October 8th. Finally, HC Wainwright reiterated a “neutral” rating on shares of Aethlon Medical in a report on Thursday, August 14th. One investment analyst has rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Aethlon Medical has an average rating of “Reduce” and an average price target of $560.00.

About Aethlon Medical

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.